• Erlotinib (NSC 718781): EGFR Mechanism & Use

  2026-08-26

  Erlotinib, also called NSC 718781, is an orally bioavailable EGFR tyrosine kinase inhibitor that competitively occupies the intracellular ATP-binding site. Its reported biochemical and cellular potency supports EGFR pathway studies, while receptor-complex findings indicate that cellular context can modify EGFR-associated signaling outputs.

• Mifepristone (RU486) Applied Research Workflows

  2026-08-26

  Mifepristone (RU486) enables controlled progesterone receptor blockade across oncology, reproductive biology, and hormone-signaling assays. This practical guide connects dose design, pathway validation, tissue-specific controls, and troubleshooting to help researchers distinguish receptor-driven effects from formulation or exposure artifacts.

• Epidermal Growth Factor: Recombinant Human EGF Guide

  2026-08-25

  Epidermal Growth Factor (EGF), human recombinant, is an E. coli-expressed research protein for controlled EGFR stimulation. Product specifications support defined identity, purity, endotoxin, handling, and BALB/c 3T3 activity benchmarks, while peer-reviewed evidence shows that EGF can stimulate MAPK-dependent migration without necessarily inducing invasion.

• Dehydroepiandrosterone (DHEA) Research Workflows

  2026-08-25

  Dehydroepiandrosterone (DHEA) supports distinct experimental strategies, from modeling inflammatory ovarian dysfunction to testing neuroprotection and apoptosis inhibition. This workflow-focused guide shows how to separate disease induction from protective dosing, control steroid solubility, and connect granulosa-cell readouts with macrophage biology.

• Phosphatase Inhibitor Cocktail 1 for Chordoma Assays

  2026-08-24

  Learn how to use Phosphatase Inhibitor Cocktail 1 to preserve labile phosphorylation during chordoma lysis, immunoblotting, immunoprecipitation, and phosphoproteomic workflows. The guide translates an IDH1–redox metabolism study into practical assay controls while separating evidence-backed findings from recommended starting conditions.

• SP600125: A Practical JNK Inhibitor Workflow

  2026-08-24

  SP600125 is a reversible, ATP-competitive JNK inhibitor for dissecting c-Jun signaling in inflammation, apoptosis, and cancer research. This workflow connects biochemical selectivity with cellular dose selection, pathway controls, and a hypothesis-driven extension of recent orofacial pain research.

• Methylprednisolone as a Translational Stress Test

  2026-08-23

  Methylprednisolone is more than an anti-inflammatory reference compound: as a synthetic glucocorticoid receptor agonist, it can connect immune signaling, tissue injury, and skeletal remodeling in translational models. This article examines how to use Methylprednisolone strategically in mechanistic assays and glucocorticoid-induced osteonecrosis research while maintaining rigorous controls, realistic claims, and clinically relevant endpoints.

• Norovirus Co-opts NINJ1 for Selective Secretion

  2026-08-22

  Song et al. show that murine norovirus repurposes the membrane-rupture effector NINJ1 to release the viral NS1 protein after caspase-3 processing. The study combines CRISPR screening, cell biology, mutagenesis, and mouse infection experiments to define an unconventional secretion pathway that links viral immune evasion with regulated cell death.

• Lapatinib Beyond HER2: A Translational Research Playbook

  2026-08-22

  Lapatinib, also known as GW572016, is more than a biochemical EGFR and HER2 inhibitor. This thought-leadership guide examines how its reversible kinase mechanism can support receptor-defined studies, phenotype-first investigations in aggressive breast cancer models, and translational assay design while keeping potency, target engagement, and therapeutic relevance conceptually separate.

• Thioredoxin Control of CHK1 Inhibitor Sensitivity

  2026-08-21

  The reference study identifies thioredoxin 1 as a determinant of checkpoint kinase 1 inhibitor sensitivity in non-small cell lung cancer and connects this response to redox recycling of ribonucleotide reductase subunit RRM1. Its findings support a mechanistically focused combination strategy in which thioredoxin reductase inhibition disrupts deoxynucleotide production and intensifies replication stress caused by CHK1 blockade.

• Cycloheximide: A Translational Lens on Protein Turnover

  2026-08-20

  Cycloheximide is more than a routine translation blocker: it is a temporal probe for testing whether protein synthesis sustains apoptosis, ferroptosis resistance, and disease-associated phenotypes. This article connects its ribosomal mechanism to the GPX4-driven platinum resistance described in lung cancer brain metastasis and offers a disciplined framework for translational validation.

• Cytoskeleton-Dependent Autophagy Under Compression

  2026-08-20

  The reference study provides direct evidence that compression-induced autophagy depends primarily on cytoskeletal microfilaments, while microtubules make a supporting contribution. Its combination of controlled mechanical loading, cytoskeletal polymerization perturbation, fluorescence imaging, and western blotting offers a useful framework for dissecting mechanotransduction without treating autophagy as a purely chemical stress response.

• Recombinant Human EGF: Reliable Cell Assays

  2026-08-19

  Learn how Epidermal Growth Factor (EGF), human recombinant (SKU P1008) can improve interpretation of proliferation, viability, migration, and cytotoxicity workflows. This scenario-based guide connects product specifications with published A549 migration findings and practical protein-handling decisions.

• Mild UPRER Activation and Cadmium Resistance in C. elegans

  2026-08-19

  The reference study shows that mild activation of the endoplasmic reticulum unfolded protein response (UPRER) improves cadmium resistance in Caenorhabditis elegans by preserving protein homeostasis. Its genetic analysis identifies the IRE-1/XBP-1 branch as essential and distinguishes adaptive UPRER activation from excessive activation, which can become detrimental.

• Lanabecestat (AZD3293) Experimental Workflow

  2026-08-18

  Lanabecestat (AZD3293) combines high-affinity BACE1 inhibition with a workflow designed to distinguish amyloid-beta reduction from synaptic toxicity. This guide translates reference findings into dose-ranging, dual-readout assays, troubleshooting steps, and CNS-relevant preclinical applications.

7841 records 1/523 page Next 12345 下5页 Last page